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Clinics 
Age and sex 
78 years old female patient. 
Previous history 
No preleukemia, no inborn condition of note. 
Organomegaly 
Hepatomegaly , splenomegaly , no enlarged lymph 
nodes , no central nervous system involvement. 
Blood 
WBC : 45 X 109/l 
HB : 6.8 g/dl 
Platelets : 116 X 109/l 
Blasts : 2% (neutrophils 82%, lymphocytes 9%, 
monocytes 7%, eosinophils 2%). RBC 5.69x109/L, 
MCHC 310x109/L, RDW 25.9% Smear left shift, 
platelet clumps, giant platelets, occasional blast cells 
and few tear drop cells seen. 
Bone marrow : Normocellular, diffusely fibrotic; 
small to large atypical megakaryocytes with 





Immunophenotype: CD11 95%, CD11c 80%, CD13 
100%, CD33 98%, CD15 92%, MPO 82%. 
Rearranged Ig Tcr: NA 
 
Pathology: NA 
Electron microscopy: NA 
Diagnosis: Post polycythemic myelofibrosis. 
Survival 
Date of diagnosis: 1998 
Treatment: Plebothomy, hydroxyurea 
Complete remission : NA 
Treatment related death : no  
Relapse : no  
Status: Alive 
Last follow up: 09-2009 
Survival: 12 years  
Karyotype 
Sample: PB, BM 
Culture time: 24h 
Banding: G-banding 
Results: 
PB 46,XX [5]/46,XX,der(6)t(1;6)(q21;p21) [25] ; BM 
46,XX,der(6)t(1;6)(q21;p21) [20] 
Karyotype at Relapse: - 
Other molecular cytogenetics technics: - 
Other molecular cytogenetics results: - 
Other Molecular Studies 
Technics: - 
Results: - 
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G- banded partial karyotypes of the patient from PB cells, showing the translocation der(6)t(1;6)(q21;p21). 
 
Comments 
We report a chromosomal translocation 
der(6)t(1;6)(q21;p21) associated with myelofibrosis 
following polycytemia vera in a 79 years old female. 
The patient was diagnosed as having polycythemia vera 
in 1998 and treated by regular phlebotomy and 
subsequently with low doses of hydroxyurea. The 
course of PV was uneventful until 2002 when her 
myeloproliferative disorder had transformed to 
myelofibrosis. Due to the unavailability of methods, 
karyotype analysis and JAK2 V617F analysis was not 
performed at the time the PV and MF were diagnosed. 
In 2009 she presented with anemia, fatigue, fever and 
hepatosplenomegaly. Chromosome analysis performed 
at that time revealed the karyotypic anomaly 
46,XX,der(6)t(1;6)(q21;p21) in bone marrow and blood 
cultures. 
Described as a balanced translocation t(1;6)(q21;p21) 
in 1 AML case in a 35 years old female with normal 
karyotype at diagnosis and with cytogenetic 
polyclonality at relapse (Davidsson et al., 2006) and in 
1 case of nodal marginal zone B-cell lymphoma (Ott et 
al., 2000). More frequently observed as an unbalanced 
translocation der(6)t(1;6)(q21;p21) resulting in partial 
trisomy for 1q21 to 1qter, and in loss of 6p21 to 6pter. 
From the 9 described cases (Najfeld et al., 2007; 
Shimazaki et al., 1999; Dingli et al., 2005) with 
der(6)t(1;6)(q21;p21), 8 patients (4 males, 4 females) 
had myelofibrosis with myeloid metaplasia (Najfeld et 
al., 2007; Dingli et al., 2005). In addition, several 
studies have reported heterogeneous 1q and 6p  
breakpoints resulting in common trisomic region of 
1q21-32 and haplo-insufficiency of gene(s) from 
different chromosome 6p breakpoints suggesting that 
gain of gene(s) at 1q21-32 and/or loss of gene(s) from 
6p21-6pter may be relevant to the pathogenesis. Our 
case, together with previously published data 
demonstrates the association of this rare chromosomal 
anomaly with primary myeloproliferative disease 
transformed to myelofibrosis (Dingli et al., 2005, 
Mertens et al., 1991, Reilly et al., 1997; Andrieux et al., 
2003 ). 
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